Suggested remit: To appraise the clinical and cost effectiveness of nivolumab with ipilimumab within its marketing authorisation for treating squamous cell carcinoma of the head and neck.
Following on from information provided to NICE by the company in May 2019, the appraisal of Nivolumab with ipilimumab for treating squamous cell carcinoma of the head and neck [ID1355] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
- Status:
- Discontinued
- Technology type:
- Medicine
- Decision:
- Prioritised
- Process:
- TA
- ID number:
- 1355
Email enquiries
If you have any queries please email scheduling@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 08 November 2022 | Discontinued. Following on from information provided to NICE by the company in May 2019, the appraisal of Nivolumab with ipilimumab for treating squamous cell carcinoma of the head and neck [ID1355] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued. |
| 16 May 2019 | Suspended. As you will be aware the Department for Health and Social Care has asked NICE to conduct an appraisal of nivolumab with ipilimumab for treating platinum-refractory squamous cell carcinoma of the head and neck. For information, the company announced that Checkmate 714 did not meet its primary endpoints in the platinum-refractory cohort and will not be pursuing a marketing authorisation application in this indication at this time. Therefore NICE has decided to suspend this appraisal from its current work programme. As this appraisal has been referred, NICE will continue to monitor any development and will update interested parties if the situation changes. |
| 16 May 2019 | Note added to the project documents |
| 11 October 2018 | Note added to the project documents |
| 18 July 2018 - 15 August 2018 | Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators |
| 21 March 2017 | In progress. Topic referred |
For further information on our processes and methods, please see our CHTE processes and methods manual